While there is no approved liver-specific drug therapy with a proven effect on NASH patients, Cenicriviroc (CVC), a dual inhibitor of CCR2 and CCR5, is among the most advanced substances in clinical development in ongoing phase 2 and 3 studies [43]. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.